Rethinking Diabetes: A Weekly Review
Malattie Metaboliche e Diabetologia
Advances in Obesity and IBD Therapies
This week we discuss two groundbreaking studies: comparing semaglutide vs liraglutide for weight management in obesity, and risankizumab as a novel treatment for ulcerative colitis. Our hosts analyze the clinical implications of these findings.
Accedi o Registrati per ascoltare questo episodio
Bibliografia
1. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
Authors: Rubino DM, Greenway FL, Khalid U, et al.
Journal: JAMA, 2022 Jan 11
PMID: 35015037
DOI: 10.1001/jama.2021.23619
2. Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials.
Authors: Louis E, Schreiber S, Panaccione R, et al.
Journal: JAMA, 2024 Sep 17
PMID: 39037800
DOI: 10.1001/jama.2024.12414
Authors: Rubino DM, Greenway FL, Khalid U, et al.
Journal: JAMA, 2022 Jan 11
PMID: 35015037
DOI: 10.1001/jama.2021.23619
2. Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials.
Authors: Louis E, Schreiber S, Panaccione R, et al.
Journal: JAMA, 2024 Sep 17
PMID: 39037800
DOI: 10.1001/jama.2024.12414
